Stockwinners Market Radar for March 02, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:07 EST Cathie Wood's ARK Investment bought 162K shares of Cerus today

18:46 EST Entergy Louisiana seeks approval to add 225 MW of solar power to generation mix - Entergy Louisiana this week filed a request with the Louisiana Public Service Commission to approve the purchase, construction and operation of nearly 225 megawatts of new solar power resources. Entergy Louisiana has selected two projects to source additional solar energy, including one in Iberville Parish that would account for approximately 175 megawatts and another in Ouachita Parish that would account for approximately 49 megawatts. If approved by the Commission, Entergy Louisiana will be able to increase its renewable portfolio and help meet the growing demand for clean generation. "This is another step toward not only reaching our own sustainability goals, but also toward helping our customers reach their sustainability goals," said Phillip May, Entergy Louisiana president and CEO. "The desire for clean power is increasing and, at Entergy, we intend to meet that desire in a way that balances our ability to continue providing reliable and affordable power. We're excited about the potential addition of nearly 225 megawatts and look forward to further expanding our portfolio of renewables as demanded by our stakeholders."

18:00 EST Exelixis trading resumes

17:51 EST Ericsson to plead guilty and pay over $206M following breach of 2019 FCPA - Ericsson has agreed to plead guilty and pay a criminal penalty of more than $206M after breaching a 2019 Deferred Prosecution Agreement DPA . Ericsson breached the DPA by violating the agreement's cooperation and disclosure provisions. Based on the same underlying criminal conduct that gave rise to the DPA, Ericsson will plead guilty to engaging in a long-running scheme to violate the Foreign Corrupt Practices Act, FCPA , by paying bribes, falsifying books and records, and failing to implement reasonable internal accounting controls in multiple countries around the world. "When the department afforded Ericsson the opportunity to enter into a DPA to resolve an investigation into serious FCPA violations, the company agreed to comply with all provisions of that agreement," said Assistant Attorney General Kenneth A. Polite, Jr. of the Justice Department's Criminal Division. "Instead of honoring that commitment, Ericsson repeatedly failed to fully cooperate and failed to disclose evidence and allegations of misconduct in breach of the agreement. As a result of these broken promises, Ericsson must plead guilty to two criminal offenses and pay an additional fine. Companies should be on notice that we will closely scrutinize their compliance with all terms of corporate resolution agreements and that there will be serious consequences for those that fail to honor their commitments." According to court documents, beginning in 2000 and continuing until 2016, Ericsson used third-party agents and consultants to make bribe payments to government officials and to manage off-the-books slush funds in Djibouti, China, Vietnam, Indonesia, and Kuwait. These agents were often engaged through sham contracts and paid pursuant to false invoices, and the payments to them were improperly accounted for in Ericsson's books and records. In 2019, Ericsson resolved this criminal conduct by entering a DPA with the department in connection with a two-count criminal information filed in the Southern District of New York. As part of the DPA, Ericsson paid a total criminal penalty of over $520 million and agreed to the imposition of an independent compliance monitor for three years. An Ericsson subsidiary, Ericsson Egypt Ltd, also pleaded guilty to a one-count criminal information charging conspiracy to violate the anti-bribery provisions of the FCPA. Reference Link

17:32 EST Lemonade to delay filing annual report on Form 10-K - Lemonade will not, without unreasonable effort and expense, be able to file its Annual Report on Form 10-K for the year ended December 31, 2022 within the prescribed time period. The company requires additional time to address the accounting for its acquisition of Metromile, which includes complex accounting and disclosure requirements. The company currently expects that it will be able to complete the necessary work to file the Form 10-K within the extension period provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended.

17:30 EST cbdMD trading resumes

17:25 EST Exelixis trading halted, news pending

17:16 EST BAE Systems awarded $245.65M Army contract - BAE Systems was awarded a $245.65M cost-no-fee, cost-sharing contract for the procurement of early order material in support of Armored Multipurpose Vehicle production. Bids were solicited via the internet with one received. Work has an estimated completion date of December 31, 2024. FY22 and FY23 weapons and tracked combat vehicle procurement, Army funds in the amount of $245.65M were obligated at the time of the award. U.S. Army Contracting Command is the contracting activity.

17:14 EST SEC Chair Gensler says crypto platforms not necessarily qualified custodians - In prepared remarks before the Investor Advisory Committee of the SEC, Chairman Gary Gensler said in part: "The Commission recently proposed a new safeguarding rule for investment advisors, building on the current, 2009 custody rule. The proposal takes up Congress's 2010 provision for us to expand the custody rule to cover all of an investor's assets, not just their funds or securities...I know there's been recent attention to this proposal regarding its intersection with crypto. Make no mistake: Our current custody rule, adopted in 2009, covers a significant amount of crypto assets. Advisers, in complying with the current custody rule, are required to safeguard investors' crypto funds and securities with qualified custodians. Make no mistake, again: Based upon how crypto trading and lending platforms generally operate, investment advisers cannot rely on them today as qualified custodians. To be clear: just because a crypto trading platform claims to be a qualified custodian doesn't mean that it is. When these platforms fail-something we've seen time and again-investors' assets often have become property of the failed company, leaving investors in line at the bankruptcy court. The new proposed safeguarding rule-in addition to expanding the custody rule's safeguards to cover all assets-would make important enhancements to the protections that qualified custodians provide. I welcome your thoughts on the proposal, as well as the letter I understand you will be submitting regarding the crypto markets. Publicly traded companies that may be impacted by this include Coinbase (COIN). Reference Link

17:07 EST Krystal Biotech director Rossi sells 40,000 common shares - In a regulatory filing, Krystal Biotech director Dino Rossi disclosed the sale of 40,000 common shares of the company on March 1 at a price of $83.2493 per share.

16:54 EST Academy Sports increases quarterly cash dividend 20% to 9c per share - Academy Sports declared a cash dividend with respect to the fiscal quarter ended January 28 of 9c per share of common stock of the company, a 20% increase from the previous quarterly dividend payment. The dividend is payable on April 13 to stockholders of record as of the close of business on March 23.

16:45 EST Interpublic Group exec sells $1.38M in common stock - In a regulatory filing, Interpublic Group disclosed that its General Counsel Andrew Bonzani sold 38.9K shares of common stock on March 1st in a total transaction size of $1.38M

16:44 EST Interpublic Group CEO sells $2.53M in common stock - In a regulatory filing, Interpublic Group disclosed that its CEO Philippe Krakowsky sold 71K shares of common stock on March 1st in a total transaction size of $2.53M

16:41 EST Mercury Systems appoints Christine Fox Harbison as Chief Growth Officer - Mercury Systems announced the appointment of Christine Fox Harbison as Executive Vice President and Chief Growth Officer, effective March 6. Reporting to Mercury CEO Mark Aslett, Harbison will be responsible for executing the company's growth strategy, driving enterprise-level capture and proposal efforts, leading strategic account management, and developing global technology partnerships and initiatives. Harbison joins the company from Northrop Grumman's Defense Systems sector, where she served as Vice President and General Manager of the Combat Systems and Mission Readiness division. Prior to that, she was Vice President of Northrop Grumman's Advanced Ground Sensors business unit and held roles of increasing importance at Raytheon Company. Harbison holds an M.S. in computer science from Old Dominion University and a B.S. in computer science and mathematics from the University of Maine. She is an active member of The Forum for Executive Women, the Women in Defense Organization, and the National Defense Industrial Association.

16:39 EST Orion Group: Austin Shanfelter to transition from Executive Chairman to Chairman - Orion Group Holdings announced that Austin J. Shanfelter will transition from Executive Chairman to Chairman of the Board of Directors, effective March 2. Shanfelter has served on Orion Group's Board of Directors since 2007 and was named Chairman in January 2021. From April to September 2022, he assumed the roles of Interim Chief Executive Officer and Interim Chief Financial Officer until Travis Boone, Chief Executive Officer and Scott Thanisch, Chief Financial Officer were appointed in September 2022. Since then, Mr. Shanfelter served as Executive Chairman to ensure a smooth leadership transition. His transition back to Chairman of the Board marks the completion of this successful transition period.

16:33 EST Veru announces FDA comments on Phase 3 study protocol - Separately, the FDA also provided comments on a proposed confirmatory Phase 3 study protocol submitted by the Company for hospitalized moderate to severe COVID-19 patients at risk for ARDS and death that could support a new EUA authorization and/or NDA approval. FDA stated that in the potential confirmatory Phase 3 clinical study design: "strong consideration should be given to appropriate time frames for interim analyses so that - should a strong efficacy signal again be observed - the trial could be stopped in an efficient time frame." Veru expects to communicate the details of the design and timing of this potential Phase 3 confirmatory study soon. It should be noted that in the U.S. Department of Health and Human Services' (HHS) fact sheet published on February 9, 2023, HHS and FDA made clear that FDA's ability to continue authorizing new COVID-19 therapeutics for emergency use is not impacted by the ending of the declaration of the U.S. public health emergency on May 11, 2023. "Our team has applied its scientific rigor and clinical expertise to expeditiously investigate sabizabulin, a microtubule disruptor, for the treatment of hospitalized critically ill COVID-19 patients during the pandemic," said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru. "We are disappointed in the FDA's decision to decline the request for an EUA because of the possibility of unknown influences, or uncertainties that may have affected the study as FDA agreed upon its review that our Phase 3 study met its primary endpoint and could not be invalidated by any known influences1, and we followed the unanimous recommendation of the Independent Data Monitoring Committee to stop the Phase 3 study because of clear clinical benefit. During our May 10, 2022 pre-EUA meeting with the FDA, the Agency indicated that our clinical data package was sufficient to support an EUA submission. Unfortunately, COVID-19 remains a serious threat as the third leading cause of death in the U.S. with over 250,000 lives lost in 2022. We lost 510 Americans to COVID-19 just yesterday despite existing FDA authorized and approved standard of care treatments. We reaffirm our strategy to deliver sabizabulin, a potentially life-saving treatment, to this vulnerable patient population facing inadequate therapeutic options to address the threat of ARDS and death from COVID-19. To that end, we will work closely with the FDA to gain clarity on advancing our sabizabulin program toward a potential new request for an EUA and an NDA submission."

16:31 EST LTC Properties sells two skilled nursing centers in New Mexico - LTC Properties "announced that it has sold two skilled nursing centers in New Mexico. The two centers, totaling 235 beds, were sold for $21.3 million, generating proceeds of $20.8 million. The proceeds will be used to pay down the Company's unsecured revolving line of credit. LTC anticipates recording a gain on sale of approximately $15 million in the 2023 first quarter. As a result of the sale, the two properties were removed from the operator's master lease, and LTC provided a rent decrease of 7.5% of the net proceeds, or approximately $1.5 million of cash rent, to the operator. The centers were built in 1975 and 1985, respectively."

16:30 EST Veru announces FDA declines to grant EUA for sabizabulin - Veru announced that the FDA has declined to grant at this time the company's request for Emergency Use Authorization, or EUA, for sabizabulin, Veru's novel microtubule disruptor, to treat hospitalized adult patients with moderate to severe COVID-19 who are at high risk for Acute Respiratory Distress Syndrome. In communicating its decision, the FDA stated that despite the FDA declining to issue an EUA for sabizabulin at this time, the FDA remains committed to working with the Company for the development of sabizabulin.

16:26 EST Runway Growth Finance reports Q4 EPS 45c, consensus 39c - Reports Q4 Total investment income $36.8M, compared to $17.6M to last year. The year-over-year improvement is primarily due to portfolio growth and an increase in interest income on investments resulting from the new loans originated. Net investment income for the quarter ended December 31 was $18.4 million, or 45c per share, compared to $10.9 million, or $0.28 per share, for the quarter December 31, 2021. revenue $, consensus $."Runway Growth delivered its fifth consecutive record quarter, which we believe validates our investment strategy in high quality, late-stage companies," said David Spreng, Founder and CEO of Runway Growth. "During 2022, Runway continued to prudently deploy leverage achieving its objective range, to unlock increasingly attractive shareholder returns while fueling minimally dilutive growth for our portfolio companies." Spreng continued, "Runway Growth's success speaks to the value of our differentiated and durable model that offers sustainable yield despite market volatility. Increasingly, later-stage companies are turning to Runway Growth to embrace debt as minimally dilutive growth capital as the cost differential between equity expands. Looking to 2023, our funnel remains robust and Runway Growth is confident in our disciplined strategy to drive earnings and long-term shareholder value."

16:18 EST Dell Technologies jumps 6% to $42.70 after Q4 results beat estimates

16:16 EST Nordstrom up 2% following Q4 report - Nordstrom shares are up 37c, or 2%, to $19.70 in after-hours trading.

16:12 EST Nordstrom announces wind-down of Canadian business - Nordstrom said: "As part of its initiatives to drive long-term profitable growth and enhance shareholder value, and after careful consideration of all reasonably available options, the Company also announced today it has decided to discontinue support for Nordstrom Canada's business operations." "We regularly review every aspect of our business to make sure that we are set up for success," said Erik Nordstrom. "We entered Canada in 2014 with a plan to build and sustain a long-term business there. Despite our best efforts, we do not see a realistic path to profitability for the Canadian business. We want to thank our team for their performance and dedication in serving customers in Canada. This decision will simplify our structure, intensify focus on our growth and profitability goals and position us to create greater value for our shareholders." Nordstrom Canada has commenced a wind-down of its operations, obtaining an Initial Order from the Ontario Superior Court of Justice under the Companies' Creditors Arrangement Act, or "CCAA," earlier today to facilitate the wind-down in an orderly fashion. Nordstrom Canada intends to wind down its Nordstrom and Nordstrom Rack stores across Canada, with the help of a third-party liquidator, and its Canadian e-commerce platform. The e-commerce platform will cease operations on March 2, 2023. The in-store wind-down is anticipated to be completed by late June 2023. The Company expects that Nordstrom Canada will be deconsolidated from the Company's financial statements as of the date of the CCAA filing. The Company expects to report approximately $300 million to $350 million of pre-tax charges related to the wind-down in the first quarter of fiscal 2023, driven primarily by the write-down of the Company's investment in Nordstrom Canada. The wind-down is expected to result in an approximately $400 million decline in total Company net sales and a $35 million improvement in total Company EBIT in fiscal 2023, relative to fiscal 2022, excluding the aforementioned charges associated with the wind-down. Nordstrom Canada operates six Nordstrom stores and seven Nordstrom Rack stores, as well as the Nordstrom.ca website, and employs approximately 2,500 people.

16:08 EST VMware sees deal to be acquired by Broadcom completed in Broadcom's FY23 - As previously reported, VMware (VMW) has entered into a definitive agreement to be acquired by Broadcom (AVGO). The transaction, which is expected to be completed in Broadcom's fiscal year 2023, is subject to the receipt of regulatory approvals and other customary closing conditions, VMware stated.

16:07 EST Elastic reports Q3 total subscription count at 19.9K vs. 19.7K in Q2 - In Q3, Elastic total subscription customer count was approximately 19,900 compared to approximately 19,700 in Q2 FY23, and over 17,900 in Q3 FY22. Total customer count with Annual Contract Value (ACV) greater than $100,000 was over 1,110, compared to over 1,050 in Q2 FY23, and over 890 in Q3 FY22. Net Expansion Rate was approximately 120%

16:03 EST DermTech initiates search to identify CEO replacement - DermTech said that John Dobak will continue to serve as president, chief executive officer and director until the earlier of the date the Board appoints a successor and September 30, 2023. The Board has initiated a comprehensive search to identify Dr. Dobak's replacement. "I'm extremely proud of what we've accomplished during my 11-year tenure as CEO having built a strong foundation for DermTech," said John Dobak, M.D., CEO, DermTech. "We've achieved widespread product adoption, secured broad payer coverage and scaled the organization for the future. I'm looking forward to finding a successor that will carry my vision forward and bring the genomic revolution to dermatologic care. I'd like to thank my team and the board for their dedication and perseverance. I'm excited about DermTech's bright future." "On behalf of the board, I want to thank John for his valuable contributions to DermTech over the past eleven years," said Matt Posard, DermTech's chairman. "We are grateful to have John's continuing leadership and support during the CEO transition."

15:20 EST cbdMD trading halted, news pending

14:09 EST CareDx trading halted, volatility trading pause

13:59 EST Coya's mission remains 'the same' as a public company, CEO tells The Fly

13:59 EST Coya Therapeutics CEO expects 'a few' data releases this year

13:49 EST GitLab increasing list price of GitLab Premium - In a blog post, GitLab stated: "Effective April 3, 2023, GitLab is increasing the list price of GitLab Premium from $19 to $29 per user per month. Existing GitLab Premium customers will have a one-time transition price of $24 per user per month automatically applied to their upcoming renewals until April 2, 2024. As GitLab's first price increase in more than five years, this new pricing for GitLab Premium reflects the evolution of GitLab from source control and CI to the most comprehensive DevSecOps Platform. Over the past five years, GitLab Premium added more than 400 features, leading to improved cycle times, enhanced developer experience, and better collaboration for our customers." Reference Link

12:46 EST OneSpan up 10% after Reuters reports company exploring sale - Shares of cybersecurity tools vendor OneSpan (OSPN) are higher after Reuters' Milana Vinn reported that the company is exploring options that include a possible sale. The company, which has become the target of activist hedge funds including Legion Partners Asset Management, is working with investment bank Evercore (EVR) on a sale process that could attract interest from other companies and private equity firms, the report said. In afternoon trading, OneSpan shares are up $1.58, or 10%, to $18.13. Reference Link

12:09 EST Build Acquisition Corp trading resumes

12:00 EST Pure Storage falls -16.2% - Pure Storage is down -16.2%, or -$4.66 to $24.13.

12:00 EST Silvergate Capital falls -44.7% - Silvergate Capital is down -44.7%, or -$6.05 to $7.48.

12:00 EST Zuora rises 13.2% - Zuora is up 13.2%, or $1.08 to $9.29.

11:53 EST Build Acquisition announces redemption of public shares subsequent dissolution - Build Acquisition Corp.announced that it will redeem all of its outstanding common stock that was included in the units issued in its initial public offering, effective as of the close of business on March 17, as the company will not consummate an initial business combination on or prior to March 19. The per-share redemption price for the public shares will be approximately $10.21. The public shares will cease trading as of the close of business on March 16. As of the close of business on March 17, the public shares will be deemed cancelled and will represent only the right to receive the redemption amount.

11:37 EST Sesen Bio stockholders approve 1-for-20 reverse stock split - Based on a preliminary count of the voting results from the meeting of stockholders, more than 88% of the votes cast were voted in favor of Proposal No. 1 to approve the issuance of Sesen Bio common stock to Carisma stockholders in the merger and approximately 86% of votes were cast in favor of Proposal No. 2, representing more than 57% of outstanding shares of Sesen Bio common stock, to approve the amendment to Sesen Bio's certificate of incorporation to effect a reverse stock split of outstanding shares of Sesen Bio common stock at a ratio of 1-for-20. The approval of Proposal Nos. 1 and 2 was needed to complete the merger. Sesen Bio currently anticipates that the reverse stock split will become effective after trading hours on March 7, 2023, such that trading of post-split Carisma common stock will commence on March 8, 2023. The merger is expected to close on March 7, 2023, subject to customary closing conditions.

11:29 EST Teladoc's BetterHelp to pay $7.8M in settlement with FTC - The Federal Trade Commission has issued a proposed order banning online counseling service BetterHelp from sharing consumers' health data, including sensitive information about mental health challenges, for advertising. The proposed order also requires the company to pay $7.8M to consumers to settle charges that it revealed consumers' sensitive data with third parties such as Facebook and Snapchat for advertising after promising to keep such data private. In its form 10-K filing, Teladoc Health previously stated: "On July 30, 2020, the company received a Civil Investigative Demand from the Federal Trade Commission as part of its non-public investigation to determine whether the company, through its BetterHelp business, engaged in unfair business practices in violation of the Federal Trade Commission Act. The company subsequently entered into settlement negotiations with the FTC in an effort to resolve all claims and allegations arising out of or relating to the FTC Investigation. During 2022, the company determined that a loss stemming from the FTC Investigation in the amount of $7.8 million is probable. An accrual of such amount is included in accrued expenses and other current liabilities in the accompanying consolidated balance sheets and in general and administrative expenses in the company's consolidated statements of operations and other comprehensive loss." Reference Link

10:54 EST Arcadia Biosciences trading resumes

10:41 EST Build Acquisition Corp trading halted, news pending

10:36 EST Huntington Ingalls, Ocan Aero partner on advanced unmanned maritime capabilities - HII and Ocean Aero initiated a strategic agreement to advance the combined capabilities of their respective unmanned maritime platforms and autonomy software solutions. The unmanned solution providers recently commenced multiple, simultaneous efforts to enhance the operational reach and duration of the platforms, collaborative autonomy behaviors, shared sensor fusion and perception capabilities, and accelerated seabed-to-shore data transmission methods.

10:20 EST Ferrari signs partnership agreement with Virtual Gaming Worlds - Ferrari N.V. announces that Ferrari S.p.A., its wholly-owned Italian subsidiary, has signed a multi-year partnership agreement with Virtual Gaming Worlds, a global technology company that specializes in the creation of online social games. Under the new multi-year agreement, effective from the first Formula 1 Grand Prix of the season in Bahrain, VGW will become Premium Partner of Scuderia Ferrari. Ferrari Chief Racing Revenue Officer, Lorenzo Giorgetti, said: "We are pleased to announce the arrival of VGW as a Premium Partner. As leaders in the gaming technology sector, they share our passion for innovation and thinking outside the box. We look forward to working with them in offering new assets and experiences to our loyal and passionate tifosi."

10:04 EST Viveon Health Acquisition, Clearday announce letter of intent to merge - Viveon Health Acquisition Corp. (VHAQ) announced that it has identified and entered into a letter of intent with a business combination target company, Clearday (CLRD). Under the terms of the letter of intent, Clearday's existing equity holders would convert 100% of their equity into the combined public company. The proposed transaction values Clearday at $250M. Viveon expects to announce additional details regarding the proposed business combination when a definitive merger agreement is executed. Completion of a business combination with Clearday is subject to, among other matters, the completion of due diligence, the negotiation of a definitive agreement providing for the transaction, satisfaction of the conditions negotiated therein and approval of the transaction by the board and stockholders of both Viveon and Clearday. "There can be no assurance that a definitive agreement will be entered into or that the proposed transaction will be consummated on the terms or timeframe currently contemplated, or at all," the company said. "Clearday is an ideal merger partner for Viveon Health as it is a transformative healthcare technology company at its inflection point of rapid growth - and addresses an underserved, large, and expanding market. As operators ourselves in the healthcare technology space, our hands-on diligence revealed the Clearday team's deliberate expansion and acceleration of their longevity-tech business plan impacting the arc from home to residential care facilities. By leveraging its operational excellence and history in longevity care and bolting on AI-driven solutions to monitor mental and physical health, its solutions can deliver real-time engagement with individuals and their families through robotic-assisted companion care designed to deliver support at any setting. I look forward to working with Jim and the rest of the Clearday team to execute their global sales channel expansion and market development plan poised to deliver growth and shareholder value," said Jagi Gill, CEO and Chairman of Viveon Health.

10:00 EST Pure Storage falls -14.8% - Pure Storage is down -14.8%, or -$4.28 to $24.52.

10:00 EST Macy's rises 10.0% - Macy's is up 10.0%, or $2.05 to $22.48.

10:00 EST Big Lots rises 13.8% - Big Lots is up 13.8%, or $1.89 to $15.62.

09:48 EST Caravelle partners with U.S. firm to export wood products from Gabon, Africa - Caravelle International Group announced that the company has established a partnership with a U.S. corporation to manufacture wood products in Gabon, Africa for export to the United States and that the government of Gabon has granted the partnership use of 165 acres of land for the location of the lumber mill. The mill will produce wood laminate flooring, plywood, and other wood products. The products will have a significant cost advantage over lumber products domestically produced in the United States because of cheaper lumber and labor in Gabon, but also because the African Growth and Opportunity Act will allow for the duty-free import of these products into the U.S. The U.S. based partner will fund the construction of the mill in Gabon and already has established distribution in the U.S. to sell these products. Caravelle will ship the wood products to the United States. Caravelle will also dry the wood products in transit, using its patent-pending CO-Tech system that uses recycled engine heat for the drying process, resulting in significant cost savings and a 6-week reduction in lead times vs. traditional kiln drying at the mill. The partners estimate that the venture will generate $200M in annual revenue within several years.

09:47 EST Aaron's falls -18.6% - Aaron's is down -18.6%, or -$2.68 to $11.72.

09:47 EST DoubleVerify rises 8.7% - DoubleVerify is up 8.7%, or $2.27 to $28.28.

09:47 EST Salesforce rises 14.2% - Salesforce is up 14.2%, or $23.80 to $191.15.

09:39 EST ZimVie trading resumes

09:37 EST Lionheart III Corp trading halted, volatility trading pause

09:35 EST Knightscope reseller places order for 30 K1 Blue Light Towers - Knightscope announced that a Florida based reseller of Knightscope technologies submitted a purchase order for 30 new K1 Blue Light Towers to support anticipated and future customer orders.

09:34 EST ZimVie trading halted, volatility trading pause

09:32 EST MarineMax promotes Cassella to EVP and Chief Accounting Officer - MarineMax earlier today announced the promotion of Anthony Cassella, Jr. to Executive Vice President Finance and Chief Accounting Officer. Cassella has served as Vice President of MarineMax since February 2016, and Chief Accounting Officer since October 2014, at which time he was appointed an executive officer of the company. Brett McGill, CEO and President of MarineMax stated, "With today's announcement, we recognize Anthony for his dedication and commitment to MarineMax and his instrumental role in helping to manage our financial affairs. He has developed an outstanding team that has supported our growth. Anthony recently celebrated his 25th anniversary as a team member of MarineMax, and we look forward to his continued success as a leader of our company."

09:30 EST Glen Burnie trading halted, volatility trading pause

09:20 EST Ford reports February U.S. sales up 21.9% to 157,606 vehicles - Ford reports February U.S. sales were up 21.9% overall to 157,606 vehicles, which includes electric vehicles sales of 3,523, up 68.1%, hybrid vehicles sales of 9,157, up 32.9%, and internal combustion sales of 144,926, up 20.5%. Reference Link

09:19 EST Cue Health announces new COVID-19 awareness collaboration with Pfizer - Cue Health (HLTH) announced a new collaboration with Pfizer (PFE) in the U.S. to raise awareness among individuals with certain underlying conditions about the risks of progressing to severe COVID-19 and the importance of seeking treatment if they test positive. Through Cue Care, Cue's same-day, at-home, test-to-treatment platform, individuals will be able to use the Cue Health App to access educational resources, including information on risk factors for progression to severe illness from COVID-19, including hospitalization or death.

09:18 EST Illumina and Myriad Genetics partner for HRD testing in the U.S. - Illumina (ILMN) and Myriad Genetics (MYGN) announced the expansion of a strategic partnership to broaden access to and availability of oncology homologous recombination deficiency - HRD - testing in the U.S. Under the agreement, Illumina TruSight Oncology 500 HRD, a research-use-only test, is now available in the US. The expanded partnership also establishes a unique companion diagnostic alliance for the pharmaceutical industry, which will enable more clinical research for gene-based, targeted therapies. The TSO 500 HRD research test aligns Myriad's MyChoice CDx HRD technology with Illumina's pan-cancer test, TSO 500. The test was codeveloped with Merck (MRK) and Myriad Genetics. Myriad and Illumina's initial partnership led to Illumina's combined HRD and TSO 500 offering launch worldwide-excluding the US and Japan-in June 2022. The product is available to order now and ready to ship in the US.

09:17 EST Greenbrier, former CEO charged by SEC for failing to disclose perks, payments - The Securities and Exchange Commission announced settled charges against Oregon-based freight transportation supply company, The Greenbrier Companies Inc., and its founder and former CEO and Chairman, William A. Furman, for failing to disclose perks provided to Furman and other Greenbrier executives and compensation Furman received from Greenbrier's charters of Furman's private plane for travel by company executives, including Furman. Greenbrier and Furman agreed to pay $1M and $100,000 in civil penalties, respectively, to settle the charges. The SEC's orders find that Greenbrier and Furman violated negligence-based antifraud and proxy provisions of the federal securities laws and that Greenbrier and Furman also committed or caused reporting, books and records, and internal accounting controls violations of the federal securities laws. Without admitting or denying the SEC's findings, in addition to penalties, Greenbrier and Furman agreed to cease-and-desist from future violations of the securities laws. Reference Link

09:12 EST AstraZeneca, Merck provide regulatory update on Lynparza sNDA - AstraZeneca (AZN) and Merck (MRK) announced that the FDA will convene a meeting of the Oncologic Drugs Advisory Committee, or ODAC, to discuss the supplemental new drug application, or sNDA, for use of Lynparza in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer, or mCRPC. The ODAC provides the FDA with independent, expert advice and recommendations on marketed and investigational medicines for use in the treatment of cancer. The FDA is not bound by the committee's guidance but takes its advice into consideration. The ODAC meeting is scheduled for April 28. AstraZeneca and Merck are committed to working with the FDA to bring Lynparza in combination with abi/pred to patients diagnosed with mCRPC. The sNDA is based on the results of the Phase 3 PROpel trial. Results from PROpel, including the primary endpoint of radiographic progression-free survival, or rPFS, were first presented at the 2022 American Society of Clinical Oncology, or ASCO, Genitourinary Cancers, or GU, Symposium and subsequently published in NEJM Evidence. Results from the final pre-specified overall survival analysis were presented at ASCO GU 2023. Lynparza in combination with abi/pred is approved in the European Union and several other countries for the treatment of adult patients with mCRPC, based on the PROpel trial.

09:11 EST 1PointFive announces plan to develop a carbon capture, sequestration hub - 1PointFive announced it has leased, through an affiliate, more than 55,000 acres along the Texas Gulf Coast, to develop a carbon capture and sequestration hub with the capacity to hold approximately 1.2 billion metric tons of carbon dioxide. 1PointFive leverages the carbon management experience of its parent company Occidental. 1PointFive has completed drilling a stratigraphic test well and subsurface assessment to characterize the site's ability to securely store CO2 and expects to apply for two Class VI permits in 2023. Jeff Alvarez, President, 1PointFive Sequestration, said, "This hub is located between two of the largest industrial corridors in Texas so captured CO2 can be efficiently transported and safely sequestered. Rather than starting from scratch with individual capture and sequestration projects, companies can plug into this hub for access to shared carbon infrastructure."

09:09 EST Philips showcases cardiology portfolio at ACC/WCC 2023 - Royal Philips is showcasing enhancements to its cardiology portfolio at the Annual Scientific Session & Expo of the American College of Cardiology/World Congress of Cardiology event. Philips' cardiology portfolio addresses ever-increasing demand for cost-effective diagnosis, treatment, monitoring, and management of patients with heart conditions such as coronary artery disease, structural heart disease, arrhythmia, and heart failure. Highlighted introductions to the portfolio include the company's latest compact portable ultrasound platform - Philips Ultrasound Compact System 5500 CV, its spectral-detector based CT scanner, Philips Spectral CT 7500, and Philips Intracardiac Echocardiography Catheter - VeriSight Pro 3D ICE.

09:08 EST Microbot Medical recently awarded grant from Israel's Ministry of Economy - Microbot Medical was recently awarded a grant from Israel's Ministry of Economy to encourage the Company's marketing activities and enhance the commercialization of the LIBERTY Robotic System in the US market, within the scope of its 'Smart Money' program. "We believe the non-dilutive grant from the Israeli government, beyond enhancing our existing marketing budget and enabling us to maintain a higher presence among our key constituents, validates our current strategy," commented Rachel Vaknin, Chief Financial Officer. "The additional funds allow us to engage with key opinion leaders, hospitals and potential strategic partners in the U.S., at a time when it's imperative that we increase our profile ahead of the regulatory and clinical phases. This is expected to allow us to seed the market and generate a high degree of market anticipation and excitement as we near the planned commercialization of the LIBERTY Robotic System." The grant, which totaled 300,000 NIS, may be repaid via a royalty mechanism from future sales of the LIBERTY Robotic System.

09:06 EST AstraZeneca says FDA to convene AdCom meeting on sNDA for Lynparza in mCRPC - The company states: "AstraZeneca (AZN) and MSD (MRK) announced that the FDA will convene a meeting of the Oncologic Drugs Advisory Committee, or ODAC, to discuss the supplemental new drug application for Lynparza ,or olaparib, in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer, or mCRPC. The ODAC meeting is scheduled for 28 April 2023. AstraZeneca and MSD are committed to working with the FDA to bring Lynparza in combination with abiraterone to patients with mCRPC. The efficacy and safety of Lynparza in combination with abiraterone and prednisone or prednisolone have been demonstrated in the PROpel Phase III trial, first presented at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), and subsequently published in the New England Journal of Medicine Evidence. Lynparza in combination with abiraterone and prednisone or prednisolone is approved in the EU and several other countries for the treatment of adult patients with mCRPC based on the PROpel trial." Reference Link

09:06 EST Accenture wins five-year $628M recompete of a contract award from CMS - Accenture has won a five-year, $628M recompete of a contract award from the U.S. Centers for Medicare and Medicaid Services, or CMS, to continue its work supporting Healthcare.gov. In 2014, Accenture Federal Services was awarded a prime contract to take over management of the Federally-Facilitated Exchange, or FFE. FFE is the backbone of Healthcare.gov, the federal government's online marketplace connecting people and small businesses with available public and private health insurance options. FFE and Healthcare.gov are central to CMS' mission in support of the Affordable Care Act to deliver affordable, quality healthcare coverage and services for tens of millions of Americans.

09:03 EST Delek US names Patrick Reilly Chief Commercial Officer - Delek US appointed Patrick Reilly as Executive VP and Chief Commercial Officer effective March 1. Reilly joins Delek from Motiva - Aramco -, where he served as VP of Trading - Crude, Clean Products & Feedstocks. Prior to Motiva, he served as a Regional Head of Trading for Gunvor as well as Global Book Leader for Marine Fuels, Fuel Oil and Refinery Feedstocks at Andeavor - Tesoro -.

08:48 EST Lexaria Bioscience announces results from diabetes animal model study - Lexaria Bioscience announces that its diabetes animal model study DIAB-A22-1 has completed and produced at least three positive outcomes including weight loss in obese diabetic-conditioned animals, together with improved triglyceride and cholesterol levels. Beginning just four days after the start of dosing with DehydraTECH-CBD, the obese rats began to lose weight. The weight loss was maximized nine days after dosing and maintained throughout the 8-week study duration. This apparent trend demonstrated roughly a 7% loss of body weight throughout the course of treatment at both DehydraTECH-CBD doses studied. Only the DehydraTECH-CBD-dosed animals weighed less at the end of the study than at the beginning, whereas the weight of the untreated obese animals trended upwards throughout the study. The lean untreated animals gained the most weight of all to actually become obese by the end of the study. Furthermore, in the DehydraTECH-CBD treated rats the weight loss trend observed did not appear to be a result of lower levels of food or water intake. Food and water intake was comparable in both the treated and untreated obese animal groups suggesting that the weight loss was more so related to enhanced metabolic function. Obesity is often accompanied by reduced activity levels, which were measured in this study via locomotor activity, the distance the animals travelled in open field observations. Interestingly, the lower dose of DehydraTECH-CBD resulted in a statistically significant improvement in locomotor activity compared to the untreated obese control rats, whereas there was no significant difference accordingly evidenced at the higher dose. As expected, activity levels for all obese rats were significantly lower than the lean control rats, although only the lower dose DehydraTECH-CBD treated rats approached the activity levels of the lean rats. Previous research has suggested that CBD may enhance motor activity through its action upon the serotonin 5-HT1A receptor. Additional investigation will be required to learn what an optimum DehydraTECH-CBD dose related to both weight loss and increased physical activity might be, given the fact that the higher dose studied may have elicited sedative-like effects of CBD triggering hypolocomotion which others have also observed upon high systemic exposure. Higher triglyceride levels in the blood can be an indication of the onset of diabetes. One of the best ways to manage triglyceride levels is to lose weight. In study DIAB-A22-1, the animals dosed with DehydraTECH-CBD showed statistically significant reductions in triglyceride levels from day 35 onwards compared to the obese animals not dosed with DehydraTECH-CBD. Once again, the lower dose of 30 mg/Kg of DehydraTECH-CBD outperformed the higher dose of 100mg/kg. By the end of the study the triglyceride levels in the animals receiving 30 mg/Kg of DehydraTECH-CBD was over 25% lower than that of the untreated obese animals. Cholesterol levels in the animals receiving DehydraTECH-CBD were also higher. There are two types of cholesterol - HDL and LDL - where HDL cholesterol is generally considered "good" and is desired and LDL cholesterol is generally considered "bad", although some studies are beginning to question whether this is true. Again, the lower dose of 30 mg/Kg appeared to outperform the higher 100 mg/Kg dose of DehydraTECH-CBD, with a trend toward increased HDL good cholesterol but with no significant effect upon LDL bad cholesterol levels compared to the untreated obese animals. The 100 mg/Kg dosed animals demonstrated increases in both desired HDL and the undesired LDL levels, with significance relative to the untreated obese animals in the latter instance. The findings with the lower dose therefore appeared to support improved physiological function relative to the diabetic state.

08:43 EST Iteris wins new $1.2M contract with Illinois Department of Transportation - Iteris announced that it has been chosen by the Illinois Department of Transportation, or IDOT, District One for select traffic signal plan preparation and plan review projects.

08:41 EST Sidus Space appoints Eric Gillenwater CCO - Sidus Space has appointed Eric Gillenwater to the role of Chief Commercial Officer or CCO , leading the company's commercial strategy and implementation to further support its overall mission of "Bringing Space Down To Earth ". With over 20 years of experience in technology and business strategy development, Gillenwater has a proven track record of driving revenue growth and profitability through effective commercial strategy development and execution. Most recently, Gillenwater served as Vice President and Business Head, Global Carrier & Enterprise for OneWeb, where he was responsible for all aspects of global commercial strategy and operations across multiple verticals. Prior to OneWeb, Gillenwater served as Vice President and Business Head, US and Europe for Bharti Airtel, where he was responsible for full operational and revenue control over direct and channel sales for Bharti Airtel US and Bharti Airtel Europe.

08:40 EST Engine Gaming's Frankly Media releases Insight platform - Frankly Media announced the release of its Insight video streaming and monetization platform. Frankly Media's Insight video streaming and monetization platform offers an integrated suite of esports/gaming, news and entertainment solutions to allow its customers to modernize their digital ecosystem, maximize their audience reach and engagement, and fully monetize their display, audio and video content. Frankly's fully integrated solution suite includes premium yield advertising solutions that include ad sales, ad operations, audience insights, revenue optimization AI and performance analytics, video streaming for Live, VOD and FAST Channels, Mobile Apps, OTT/CTV Apps, Website/CMS and Audience Engagement widgets.

08:39 EST PharmAla named exclusive MDMA supply partner to Awakn Life Sciences - PharmAla Biotech Holdings has been named the exclusive MDMA supplier to Awakn LS Europe Holdings.

08:39 EST MyMD Pharmaceuticals: DEA determines Supera-CBD not a controlled substance - MyMD Pharmaceuticals announced that the U.S. Drug Enforcement Administration DEA has conducted a scientific review and determined that investigational cannabinoid Supera-CBD is not currently considered a controlled substance or listed chemical. The scientific review of the chemical structure of Supera-CBD was conducted in accordance with the Controlled Substances Act CSA and its governing regulations. "Currently, all FDA-approved cannabinoid products are considered controlled substances, with the exception of Epidiolex, and although plant-derived cannabidiol, CBD, is unscheduled, its use by military and federal civilian employees currently is prohibited without a valid prescription. This decision by the DEA is tremendous news for Supera-CBD and we are very pleased that our product candidate will not require DEA scheduling during development," said Christopher Chapman, MD, President, Director, and Chief Medical Officer at MyMD Pharmaceuticals. "We look forward to studying Supera-CBD's potential to improve upon the benefits of CBD while retaining its safety and tolerability without intoxicating effects." "It is a tremendous benefit to be able to conduct drug development without the burden of dealing with a scheduled product," said Dr. Jack Henningfield, Vice President, Research, Health Policy, and Abuse Liability at Pinney Associates, Inc. "We look forward to continuing our support of MyMD Pharmaceuticals as Supera-CBD advances through development."

08:36 EST Adeia extends IP license agreement with Verizon - Adeia (ADEA) announced that Verizon (VZ) has entered into a multi-year extension of its license to Adeia's media patent portfolio. "Our patent license extension with Verizon further confirms the value and longevity of Adeia's intellectual property portfolios, including in the U.S. pay-TV market," said Dr. Mark Kokes, Adeia's chief licensing officer and general manager, media. "We are excited to extend our relationship with Verizon, one of the world's leading providers of technology, communications, information and entertainment products."

08:35 EST Kroger sees FY23 CapEx $3.4B-$3.6B, free cash flow $2.3B-$2.5B, tax rate 23%

08:35 EST Steakholder Foods appoints Eitan Noah as CFO - Steakholder Foods' current VP of Finance, Eitan Noah, will be assuming the position of CFO, as its current CFO, Guy Hefer, has decided to step down from his role for personal reasons. Eitan Noah will assume the CFO role on March 23 following the publication of the company's annual report. Noah has been VP of Finance since January 2021. Before his tenure as VP Finance at Steakholder Foods, Noah was Director of Finance at Inception XR and Controller and FP&A Manager at Fluence Corp.

08:35 EST Kroger pauses share repurchase program - Kroger expects to continue to generate strong free cash flow and remains committed to investing in the business to drive long-term sustainable net earnings growth, as well as maintaining its current investment grade debt rating. The Company expects to continue to pay its quarterly dividend and expects this to increase over time, subject to board approval. Kroger has paused its share repurchase program to prioritize de-leveraging following the proposed merger with Albertsons. Kroger's net total debt to adjusted EBITDA ratio is 1.57, compared to 1.63 a year ago. The company's net total debt to adjusted EBITDA ratio target range is 2.30 to 2.50.

08:33 EST Macy's y/y sales performance softer in 1H23 vs. 2H

08:33 EST Imax and Cineplexx Austria sign agreement for three new Imax locations - Imax and Cineplexx Austria announced an expansion of their partnership with an agreement for three new Imax with Laser systems in Europe. Cineplexx, Austria and Southeastern Europe's largest cinema operator, will deploy the new systems in Austria and Kosovo, the first Imax system for the country. Cineplexx currently operates eight Imax locations across Austria, Serbia and Greece, with one additional location in backlog prior to this agreement.

08:31 EST NexGel acquires 50% interest in JV with CG Laboratories - NEXGEL announced the acquisition of 50% interest in a newly formed joint venture, JV, CG Converting and Packaging, LLC, with C.G. Laboratories for its converting and packaging business. The agreement is effective March 1, 2023. "We are excited to announce this strategic opportunity with one of our largest and long-standing customers," said Adam Levy, Chief Executive Officer of NEXGEL. "CG Labs converting and packaging division is already a successful and profitable business that has been one of NEXGEL's largest customers for over 15 years. This transaction immediately increases capacity, improves margins and streamlines our supply chain. There are also significant synergies between the two operations, allowing for the onboarding of potential finished goods customers that in the past were not large enough to be practical for CG Labs or might be too large for NEXGEL to on board alone, as well as combined marketing and customer outreach." Under the terms of the agreement, this JV, named CG Converting and Packaging, LLC, will be owned 50% by NEXGEL. CG Labs will contribute its existing converting and packaging division to the JV, including, but not limited to, its facilities, equipment, employees, and customers. NEXGEL will contribute $500,000 to the JV to be used for equipment and facility upgrades as well as general corporate purposes.

08:18 EST Canacol Energy says gas sales averaged 191 MMscfpd in February - Canacol Energy provided the following information concerning its February 2023 natural gas sales and near term drilling program. Realized contractual natural gas sales were 191 million standard cubic feet per day for February 2023. The Corporation is currently running intermediate casing to 10,300 feet measured depth. Upon completion the drilling will continue to a planned total depth of approximately 16,000 ft md. The Natilla 1ST is targeting gas charged sands of the Porquero and Cienaga de Oro reservoirs. The Corporation anticipates the well will take approximately 6 more weeks to drill, complete, and test.

08:17 EST Charles River Associates expands share repurchase program by $20M - CRA's board of directors authorized a $20M expansion of the company's existing share repurchase program, in addition to the $22.9M currently remaining under the program. CRA may repurchase shares of its common stock in the open market or in privately negotiated transactions in accordance with applicable insider trading and other securities laws and regulations. The timing, amount and extent to which CRA repurchases shares will depend upon market conditions and other factors it may consider in its sole discretion.

08:16 EST Spirax-Sarco to host webinar: Steam in Hospitals - Spirax Sarco announced their live free webinar: Steam In Hospitals. This one-hour online event will be held Wednesday, March 22, 2023 at 11:00 AM, Eastern time. Webinar attendees will learn steam system best practices for hospitals and how to improve steam quality in their hospital, while also mitigating the patient risk from infections and unsterile equipment. How to achieve sustainability goals will also be discussed during this live event. This exclusively designed webinar is for Hospital Safety Managers, Operations Managers, Sterilization Managers, Facility Managers and Directors, and Healthcare Engineers.

08:15 EST Labrador Gold report results from recent drilling targeting Appleton Fault Zone - Labrador Gold announces results from recent drilling targeting the highly prospective Appleton Fault Zone over a 12km strike length. The drilling is part of the Company's ongoing 100,000 metre diamond drilling program at its 100% owned Kingsway Project. "The long intersection at the HTC zone, significantly extending this zone to depth, is encouraging especially as we also continue to step out towards the northeast. We have also made significant step outs in recent holes to the southwest, with assays pending, such that Big Vein has now been drilled over a strike length of approximately 590 metres and remains open in both directions." said Roger Moss, President and CEO. "Two rigs continue drilling at Big Vein to test for extensions of the mineralization to both the northeast and southwest."

08:14 EST Macy's sees low single digit annual net sales beginning in 2024 - Targeting low single digit annual net sales and comparable owned plus licensed sales growth beginning in 2024.

08:13 EST Rover Group launches Rover Gear walking collection - Rover announced Rover Gear-the company's first-ever line of branded merchandise. Rover Gear is launching with a walking collection that includes comfortable and easy-to-use walking gear. "Rover designed Rover Gear with safety in mind using insights from pet experts, pet parents, and real dog walkers who have been part of 75M Rover services booked," the company said. "We're always looking for new ways to make it easier for everyone to have the unconditional love of a pet in their life and believe Rover Gear is another element that delivers on our mission," said Lara Bain, merchandising and product expert at Rover. "With the launch of Rover Gear, we wanted our customers to feel confident in knowing that their dog's needs-and their needs-are met, wherever their walk takes them."

08:11 EST Ideanomics subsidiary selected by global OEM for new two-wheel electric vehicle - Ideanomics subsidiary Energica Motor, maker of electric motorcycles, and a major global original equipment manufacturer, or OEM, are collaborating to develop a new line of electric two-wheel vehicles. Energica Inside, a business unit of Energica, is providing design and engineering services. Energica Inside provided a feasibility study to identify a final configuration for an off-road electric vehicle platform. The company's engineers and designers performed a technical assessment of the OEM's existing platform and battery pack to validate the definitive product battery specification. Energica Inside already has several projects underway, including a collaboration with U.S. electric tractor manufacturer Solectrac. Energica Inside is helping Solectrac develop its next generation of electric tractors.

08:10 EST Lithium Americas commences construction at Thacker Pass - Lithium Americas announces the commencement of construction at its 100%-owned Thacker Pass lithium project in Humboldt County, Nevada, following the receipt of notice to proceed from the Bureau of Land Management, BLM. "Starting construction is a momentous milestone for Thacker Pass and one we have been working towards for over a decade," said Jonathan Evans, President and CEO. "We are excited about the prospect of generating economic growth in Northern Nevada and playing a major role in the domestic lithium supply chain for electric vehicles."

08:09 EST Galectin Therapeutics provides final randomization status of NAVIGATE - Galectin Therapeutics announced that in late December 2022, it ended the enrollment of new patients into NAVIGATE, its phase 2b/3 study of belapectin in patients with liver cirrhosis caused by non-alcoholic steatohepatitis, NASH. The last patient was randomized into NAVIGATE at the end of February 2023. NAVIGATE has randomized 357 patients, above its initial objective of approximately 315 patients. NAVIGATE is the first study of its kind and is a global effort that recruited patients in 14 countries and on five continents. The main efficacy objective is the primary prevention of esophageal varices. Joel Lewis, the Company's President and Chief Executive Officer said: "We are gratified to reach this important milestone. The last randomization will allow us to focus on efficiently executing our program and other stated goals for the rest of the year. On behalf of the whole team at Galectin Therapeutics, I again want to personally thank our investigators and their teams, along with all of the patients in the trial, for participating in this innovative study. I also am extremely grateful for the commitment and dedication of all of our employees in enabling us to reach this milestone."

08:08 EST Akamai to acquire Ondat, terms not disclosed - Akamai announces that it has entered into a definitive agreement to acquire Ondat, a cloud-based storage technology provider with a Kubernetes-native platform for running stateful applications anywhere at scale. Ondat's technology delivers persistent storage directly onto any Kubernetes cluster for running business-critical, stateful applications safely across any public, private and hybrid clouds. The acquisition of Ondat's cloud storage technology and its industry-recognized talent is intended to strengthen Akamai's cloud computing offerings. Ondat's employees, including founder and chief technology officer Alex Chircop, will join Akamai's cloud computing business. Ondat, headquartered in London, U.K., is a privately funded company. The acquisition is expected to close in the first quarter of 2023. Akamai anticipates no material impact to the company's financial guidance for 2023 as a result of the transaction.

08:07 EST Bionano Genomics announces publication of results from OGM trial - Bionano Genomics announced two publications detailing results from the clinical trial designed to support establishing optical genome mapping as part of the standard of care in diagnosis of genetic disease for postnatal patients. The clinical trial is designed to compare OGM to SOC, including concordance, reproducibility, technical success rate and the rate of detecting reportable findings in cases. A peer-reviewed publication covered an interim readout of the study, which showed OGM's high technical performance and reproducibility across sites versus SOC analysis. The preprint publication extended the study to additional patients and measured the rate of detecting reportable findings by OGM compared to that of SOC methods in analysis of samples from individuals with neurodevelopmental disorders, including developmental delay, intellectual disability and autism spectrum disorder.The peer-reviewed publication describes OGM performance metrics like first pass success rate and reproducibility from site-to-site, operator-to-operator and run-to-run for the first time ever and for the largest number of samples investigated with OGM to date. Key findings were reported as follows: Unblinded concordance with standard of care; Partially concordant with SOC - 0.5%; Blinded concordance with SOC - 97.6%; First-pass success rate for OGM - 90.2%; Overall success rate - 98.8%; 100% agreement on Fragile X syndrome calls for "full expansion or not full expansion" in 401 samples; The pre-print publication describes OGM performance metrics compared to SOC methods for challenging samples from diagnosed and undiagnosed rare diseases. Key findings were reported as follows: Concordance for all combined samples against SOC methods - 99.6%; For a subset of 79 prospectively collected samples from patients suspected of a genetic disorder, SOC had reportable findings in 19 cases [24%]; OGM had reportable findings in 27 cases, corresponding to a 42% increase in the number of cases with reportable findings when OGM was used; For another subset of cases consisting of 135 retrospectively collected samples from patients suspected of autism spectrum disorders, SOC found reportable variants in 63 samples; OGM identified reportable variants in 83 samples corresponding to a 32% increase in the number of cases with reportable findings when OGM was used. Authors of the peer-reviewed publication concluded that study results demonstrate the high technical performance of the OGM workflow for postnatal samples. The authors reported that intersite, interrun, and intrarun performance demonstrates the reproducibility of the OGM workflow, suggesting the potential for easy adoption and validation. The authors further underscored that OGM is not limited to copy number variation analysis alone, but can also resolve balanced structural rearrangements, size repeat expansions like FMR1 and repeat contractions like D4Z4 and noted that OGM identified additional variants that were undetected by SOC. In summary, the authors concluded that a single approach, like OGM, can allow genetic laboratories to provide rapid results with a cost-effective solution. The pre-print publication results demonstrate the potential of an OGM workflow to detect all classes of SVs with higher resolution, including aneuploidies, triploidy, translocations, inversions, insertions, microdeletions, microduplications, nucleotide repeat expansions or contractions, and absence of heterozygosity. In contrast to variants of uncertain significance that are detected by microarray, which are limited to gains and losses, the VUSs reported by OGM include multiple types of SVs, several of which reside in candidate genes associated with the phenotype. The authors concluded that OGM can offer a simple and streamlined workflow that can detect relevant genomic aberrations and mitigate the need for numerous testing platforms and time-consuming wet lab work, potentially improving lab performance by reducing the associated time and costs.

08:07 EST NV5 Global acquires Gaudet Associates - NV5 Global announced that it has acquired Gaudet Associates. Gaudet Associates has worked on behalf of owners to oversee new facility development and renovations in Florida for 35 years and strengthens NV5's existing owner representation capabilities. The acquisition was made with a combination of cash and stock and will be immediately accretive to earnings. "With the fastest growing population in the nation and recent growth in tourism, Florida building owners are turning to owner representatives for construction and renovation oversight to meet the needs of Florida's residents and visitors," said Dickerson Wright, PE, Chairman and CEO of NV5. "Gaudet Associates has been serving the Florida market for over three decades, and we look forward to the contributions that it will bring to our existing owner representation group in the state."

08:06 EST Macy's: Consumer in better shape than 2019, but prices for services higher - Comments taken from Q4 earnings conference call.

08:05 EST MarineMax announces Anthony Cassella as CFO - MarineMax announced the promotion of Anthony E. Cassella, Jr. to Executive Vice President Finance and Chief Accounting Officer. Cassella has served as Vice President of MarineMax since February 2016, and Chief Accounting Officer since October 2014 at which time he was appointed an Executive Officer of the Company. Since joining MarineMax in 1998, Mr. Cassella has excelled in numerous positions of increasing responsibility, including Director of Accounting and Shared Services from October 2007 until February 2011 and Regional Controller from March 1999 until October 2007.

08:04 EST Papa John's chairman Jeffrey Smith resigns, Christopher Coleman succeeds - Papa John's announced that Jeffrey Smith, CEO of Starboard Value, and chair of the Papa Johns board of directors has resigned from the board effective as of March 1. Christopher Coleman, a Papa Johns director since 2012, has been appointed the new independent chair of the board.

08:02 EST Worksport's first factory job fair attracts roughly 100 applicants - Worksport was pleased to welcome close to 100 applicants seeking employment at the Company's recent job fair held on February 23, 2023 at its 220,000 sq. ft. Western New York manufacturing facility. The participants ranged from those desiring production jobs on the factory floor to quality control and engineering candidates.

08:02 EST Home Depot launches new Virtual Kids Workshops on Roblox - The Home Depot (HD) launched a new Virtual Kids Workshop, an experience in Roblox's (RBLX) Redcliff City that challenges gamers to play and learn by collecting materials to build projects. The Home Depot's debut into the metaverse marks its latest investment in the future of interconnected experiences - all while introducing a whole new generation of doers to home improvement and the joy of building.

08:01 EST TD Bank, First Horizon continuing to engage with regulators on applications - TD Bank (TD), in slides being president on its Q1 earnings conference call, said it and First Horizon (FHN) are continuing to engage with regulators on applications. The companies, which extended the merger agreement to May 27, are continuing conversion planning and developing end-state strategies for integration across all lines of business and corporate functions. They are continuing to engage with and communicate with First Horizon employees and internally on deal closing, integration and conversion progression. Additionally, TD said it is in discussions with First Horizon about a potential further extension.

07:49 EST ARway enters museum AR wayfinding pilot, partnership with ERNACT - ARway Corporation announced a digital transformation pilot project for an Interactive Augmented Reality experience with wayfinding and content for the Donegal County Museum. This pilot is part of a larger European digital transformation project through ERNACT called The Public Link. The pilot will run for 60 days. It represents the first project in what is anticipated to be part of a much larger opportunity for similar projects all over the European Union. The ERNACT network of regions currently has 12 live Digital Transformation projects, involving 50 regions and 60 organizations.

07:45 EST Diversified Energy completes acquisition of upstream assets from Tanos - Diversified Energy announces the closing of its acquisition of certain upstream assets and related facilities in Texas, within the Company's Central Region, from Tanos Energy Holdings II LLC, a portfolio company of Quantum Energy Partners. Concurrently, the Company also completed an acquisition-related redetermination of the borrowing base of its Sustainability Linked Loan resulting in a 50% or $125 million increase in the borrowing base to $375 million.

07:41 EST Entourage Health launches new Color Cannabis, Saturday Cannabis products - Entourage Health announces the expansion of its brand portfolio with new offerings. The Company's Color Cannabis and Saturday Cannabis adult-use products include distinct cultivars, large-format flower and infused pre-rolls, now available in Ontario and Alberta, with expansion into the rest of Canada over the next few months.

07:40 EST Saia provides first quarter LTL operating data - Saia is providing LTL shipment and tonnage data for the first two months of the first quarter. In January 2023, final LTL shipments per workday declined 4.0%, LTL tonnage per workday declined 3.7% and LTL weight per shipment increased 0.2% to 1,442 pounds compared to 1,439 pounds in January 2022. In February 2023, LTL shipments per workday declined 7.6%, LTL tonnage per workday declined 7.6% and LTL weight per shipment declined 0.1% to 1,405 pounds compared to 1,406 pounds in February 2022.

07:38 EST Marathon Gold provides inaugural Valentine construction progress report - Marathon Gold provides an update on construction progress at its 100% owned Valentine Gold Project located in central Newfoundland. Matt Manson, President and CEO, commented: "We are providing today the first of what will be quarterly progress reports on construction at the Valentine Gold Project... Our permanent camp, which will initially have 352 beds, is nearing completion and will be available to support the major construction activities around the mill, which have commenced, and at the Tailings Management Facility, which are scheduled to begin in the second quarter... After a winter start-up with a new team using new equipment and field-based maintenance services, we saw production rates achieved in February which will successfully support our construction schedule. We continue to see the sector-wide inflationary pressures reported by our peers, especially in labour and contractor rates, and are working to mitigate these through our procurement practices and scope control. Overall, this has been a solid start-up for what will be Atlantic Canada's largest gold mine."

07:37 EST Selecta Biosciences sees cash runway into mid-2024 - Selecta had $136.2 million in cash, cash equivalents, marketable securities, and restricted cash as of December 31, 2022, as compared to cash, cash equivalents, marketable securities, and restricted cash of $129.4 million as of December 31, 2021. Selecta believes its available cash, cash equivalents, restricted cash, and marketable securities will be sufficient to meet its operating requirements into mid-2024

07:35 EST Vision Marine announces opening of second electric boat rental in California - Vision Marine Technologies announce the opening of its second electric boat rental operation in Portside Ventura, California. The operations will be located at 1196 Portside Drive Ventura and is planned to open on April 1st, 2023. The new rental operations will serve multiple purposes, including testing, validating, and training for west coast boat manufacturers. Specifically, the operations will be used to provide evaluation and training on Vision Marine's fully electric E-Motion 180E propulsion system and outboard technology. "We are excited to bring our electric boating operations to Portside Ventura. Our electric boats are not only an environmentally friendly alternative to traditional gasoline-powered boats but will create a unique experience for the residents and the general public," stated Alex Mongeon, co-Founder & CEO of Vision Marine.

07:34 EST Dyne Therapeutics expects cash to fund operations through 2024 - Cash, cash equivalents and marketable securities were $256.0 million as of December 31, 2022, which is anticipated to fund operations through 2024.

07:32 EST Prenetics announces formation of scientific advisory board - Prenetics Global (PRE) announces the formation of a new Prenetics Scientific Advisory Board to provide strategic input based on their scientific knowledge and clinical expertise to help guide the further development of Prenetics' diagnostic cancer genomics platform. Prenetics' SAB appointees include: Prof. Mok will lead the SAB and currently serves as Chairman of the Department of Clinical Oncology of Chinese University of Hong Kong, is a non-executive director of AstraZeneca (AZN), and an independent director of HUTCHMED Limited. Prof. Pasi Janne is a translational thoracic medical oncologist at the Dana Farber Cancer Institute and Professor of Medicine at Harvard Medical School. Prof. Yang has been a professor in the department of internal medicine at the College of Medicine for 27 years. Dr. Hua Chien Chen is the Co-founder and the Chief Scientific Officer of ACT Genomics. Dr. Frank Ong, MD. Chief Medical Officer for Prenetics and Interim CEO for ACT Genomics. Dr. Lawrence Tzang is the Co-Founder of Prenetics and has served as its Chief Scientific Officer and director since its founding in 2014.

07:31 EST Woodside Energy enters option agreement on Pel 87 in Orange Basin - Sintana Energy announced that Woodside Energy, a wholly-owned subsidiary of Woodside Energy Group has entered into an agreement whereby it has the option to acquire a 56% Participating Interest in Petroleum Exploration License 87, in consideration for, among other things, paying the full cost for a 3D-seismic survey covering an area of at least 5,000 square kilometres within the area the subject of PEL 87 at an estimated cost of US$35 million. Woodside will have a period of at least 180 days after the delivery of the seismic survey data to exercise that option. If Woodside exercises its option, it has agreed to enter into a farmout agreement whereby Woodside will carry the existing joint venture partners during the drilling of the first exploration well to be drilled on the Licence Area after the completion of the seismic survey. It is anticipated that seismic surveying will start in March 2023 with fast-track processed results expected in late June of this year. Custos Investments retains a 15% interest in PEL 87 and benefits from this carry and other elements of related farmout and joint operating agreements. Sintana owns an indirect minority interest in Custos. PEL 87 covering an area of 10,970 sq km, hosts the large Saturn turbidite complex on-trend with the recent major oil discoveries made in the Orange Basin including Total's Venus-1 discovery and Shell's Graff-1 and La Rona-1 and recent Jonker-1 discoveries have proven a working light oil system offshore Namibia. Shell has now commenced a multi-well drilling program with Jonker-1 near the Graff discovery, and Total has announced its intention to deploy half its global exploration budget for 2023 using two rigs to drill further exploration and appraisal wells in the Orange Basin.

07:28 EST Verano Holdings opens MUV Winter Springs in Florida - Verano Holdings announced the opening of MUV Winter Springs on Friday, March 3, 2023; this is the Company's 66th Florida dispensary and 125th retail outlet nationwide. MUV Winter Springs, located at 1315 Tuskawilla Road, is open Monday through Saturday from 9 a.m. to 7 p.m. and Sunday from 11 a.m. to 5 p.m., local time.

07:27 EST GFG upsizes private placement financing to C$4.2M - GFG Resources announces that due to investor demand it has increased the size of its previously announced private placement financing to raise gross proceeds of up to C$4.2 million. In connection with the Offering, the Company is pleased to announce that Alamos Gold Inc. has committed to purchasing securities to increase their position to a 9.99% interest in the Company upon completion of the Offering. The Offering will consist of any combination of units of the Company at a price of C$0.13 per Unit; common shares of the Company that will qualify as "flow-through shares" for the purposes of the Income Tax Act at a price of C$0.15 per FT Share; and premium units of the Company at a price of C$0.1866 per Premium Unit, subject to maximum aggregate gross proceeds of up to C$4.2 million. Each Unit shall consist of one common share of the Company and one-half of one share purchase warrant, with each whole share purchase warrant entitling the holder thereof to acquire one additional common share of the Company at an exercise price of C$0.18 for a period of 36 months from the date of issuance. Each Premium Unit shall consist of one FT Share and one-half of one Warrant. If during the exercise period of the Warrants the closing price of the common shares of the Company is at a price equal to or greater than $0.26 for a period of 10 consecutive trading days, GFG will have the right to accelerate the expiry date of the Warrants by giving notice, via a news release, to the holders of the Warrants that the Warrants will expire on the date that is 30 days after the issuance of said news release. The gross proceeds raised from the sale of the FT Shares and Premium FT Shares will be used for exploration activities in Ontario that will qualify as "Canadian Exploration Expenses". The net proceeds raised from the sale of the Units and the Warrants comprising, in part, the Premium Units, will be used for exploration activities on the Company's projects in Ontario as well as for general working capital purposes. The Offering is scheduled to close on or about March 15, 2023 and is subject to certain conditions, including, but not limited to, the receipt of all necessary approvals, including the approval of the TSX Venture Exchange. The Offering is being made by way of private placement in Canada and such other jurisdictions as the Company may determine.

07:26 EST Emerita Resources announces assay results from 7 holes at La Romanera Deposit - Emerita Resources announces assay results from seven additional drill holes from the delineation drilling program at La Romanera Deposit at its wholly owned Iberian Belt West project. IBW hosts three previously identified massive sulphide deposits: La Infanta, La Romanera and El Cura. All deposits are open for expansion along strike and at depth. According to Ian Parkinson, Executive Vice President of Corporate Development for Emerita, "These deeper holes are particularly noteworthy in that they represent some of the higher grade and thickest intercepts drilled to date and remain open for further expansion of the deposit at depth. It is very exciting to see such wide mineralized intercepts. The excellent gold and silver grades are expected to add significant value to the deposit. These results will be included in our maiden resource estimate."

07:25 EST OneWater Marine appoints Bauza to board of directors - OneWater Marine (ONEW) announced the appointment of Carmen Bauza to the Company's Board of Directors as an additional independent director, effective as of March 1, 2023. This appointment will increase the size of the Board from eight to nine directors, seven of whom are independent. As part of her inclusion on the board, Bauza will also serve on the Audit and Compensation Committees with her fellow board members. Bauza currently serves as a member of the board of directors for Zumiez (ZUMZ), Destination XL Group (DXLG), and the board of managers of Claire's Stores.

07:22 EST Macy's sees FY23 gross margin about 38.7%-39.2% - Sees FY23 CapEx approximately $1B.

07:19 EST Gilat Satellite, Hispasat expand strategic partnership - Gilat Satellite Networks announced that Hispasat selected Gilat's SkyEdge IV platform for operation with its Amazonas Nexus satellite. This marks an expansion of the strategic partnership between the two companies that will enable Hispasat to deliver high-performance, satellite-based fixed data and mobility services. SkyEdge IV, Gilat's next generation platform, is designed to operate with new, adaptable, highly flexible, high throughput and very high throughput satellites, HTS/VHTS, to provide end-users the required capacity where and when needed. "Following a comprehensive technological assessment, we concluded that Gilat's SkyEdge IV platform best meets our needs to operate most efficiently with the advanced capabilities of our new Amazonas Nexus satellite," said Jose Sanchez, Chief Solutions Officer of Hispasat. "We plan to leverage Gilat's SkyEdge IV platform to expand our service coverage in Latin America during the second half of 2023."

07:18 EST Avadel Pharmaceuticals requests final FDA approval for LUMRYZ - Avadel Pharmaceuticals (AVDL) announced that it has submitted an amendment to the U.S. Food and Drug Administration, FDA, requesting final approval for LUMRYZ for the treatment of cataplexy or excessive daytime sleepiness, EDS, in adults with narcolepsy. This submission follows a unanimous 3-0 panel decision by the United States Court of Appeals for the Federal Court on February 24, affirming the previous ruling from the United States District Court for the District of Delaware, ordering Jazz Pharmaceuticals (JAZZ) to delist its U.S. Patent No. 8,731,963 from FDA's Orange Book. Jazz submitted its request to delist the REMS Patent to FDA on February 28. Based on extensive patient and physician research, Avadel estimates the total potential patient population for once-at-bedtime LUMRYZ could be greater than 30,000, and expects LUMRYZ, if approved, to be the treatment of choice for patients suffering from narcolepsy-related EDS or cataplexy. The current twice-nightly oxybate market for narcolepsy in the U.S. is estimated at $1.8 billion comprised of approximately 16,000 patients. In addition, Avadel estimates that in the last three years, 10,000 - 15,000 patients have discontinued their twice-nightly oxybate use, many due to complications associated with middle-of-the-night dosing. Based on the estimated total potential patient population, the market opportunity could be in excess of $3.0 billion annually.

07:16 EST JATT Acquisition reports SEC declares Zura Bio registration statement effective - JATT Acquisition announced that the U.S. Securities and Exchange Commission, or SEC, has declared its registration statement on Form S-4 pertaining to the proposed business combination with Zura Bio as effective.

07:14 EST Intercept sees FY23 Ocaliva net sales $310M-$340M - In addition, the company is announcing 2023 non-GAAP adjusted operating expense guidance of $360 million to $390 million.

07:13 EST Natera announces commercial coverage policies for residual disease test - Natera announced the company's first commercial coverage policies for its molecular residual disease test, Signatera, including its first pan-cancer coverage policy for adjuvant, recurrence monitoring, and treatment monitoring. Effective March 1, Blue Shield of California now provides commercial coverage of Signatera for plan members diagnosed with any solid tumors. Specifically, the policy describes tumor-informed ctDNA testing with Signatera as medically necessary for patients with stage I-IV cancer to provide information for adjuvant or targeted therapy; and/or monitoring for relapse or progression, including but not limited to the use of immunotherapy. In addition, effective January 1, Blue Cross and Blue Shield of Louisiana is providing coverage of serial testing with Signatera for plan members diagnosed with colorectal and muscle invasive bladder cancer and for pan-cancer immunotherapy monitoring.

07:11 EST Big Lots CEO says 'focused on growing margin, reducing expenses' - Bruce Thorn, President and CEO of Big Lots stated, "Despite the extremely difficult consumer environment throughout 2022, we've taken action to strengthen and transform our business model. Against that backdrop, we made sequential progress to improve our margins, tightly manage expenses, and right-size our inventories over the last few quarters. Even though our furniture business was adversely impacted by the unexpected closure of our largest vendor, we were able to deliver fourth quarter sales and gross margins that were in line with guidance. Further, our year-over-year inventories came down materially to appropriate levels. We also saw favorability in SG&A, as we tightly managed costs, and have further strengthened our balance sheet through asset monetization efforts. I remain impressed by the agility and efforts of the team, who once again delivered on our targets under challenging conditions. As we enter 2023, we remain excited about the opportunity to provide more value to our customers, while improving our sales and earnings momentum as the year progresses. We continue to accelerate the transformation of our business through key action points. These include offering even more compelling opening price points and better bargains and treasures, which are easier to find and more convenient to shop. In addition, we will continue to take strides to meet our customer's needs, grow our relevance, and be more efficient across our fleet. We remain focused on growing margin, reducing expenses, and making highly disciplined investment decisions."

07:10 EST FDA accepts Aldeyra's ADX-2191 NDA for priority review to treat lymphoma - Aldeyra Therapeutics announced that the U.S. Food and Drug Administration accepted for Priority Review the New Drug Application for ADX-2191, methotrexate injection, USP , an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma. The FDA assigned a Prescription Drug User Fee Act PDUFA date of June 21. The FDA noted that no potential filing review issues have been identified. "The FDA's decision to grant Priority Review with a PDUFA date four months from NDA acceptance underscores the significant need for an FDA-approved treatment of primary vitreoretinal lymphoma, a rare but potentially fatal cancer," stated Todd C. Brady, M.D., Ph.D., Aldeyra's President and Chief Executive Officer. "We are working closely with the FDA during the review process to bring ADX-2191 to patients as quickly as possible, and plan to launch ADX-2191 in the United States in the second half of this year, pending approval by the FDA." The NDA submission is supported by a combination of more than three decades of published literature on the safety and efficacy of methotrexate, the active ingredient of ADX-2191, for the treatment of primary vitreoretinal lymphoma, in addition to safety data from the recently completed Phase 3 GUARD Trial of ADX-2191 in patients with proliferative vitreoretinopathy. During the Phase 3 GUARD Trial, no safety signals were observed, and ADX-2191 was well tolerated; there were no observed treatment-emergent serious adverse events. The most common adverse event associated with ADX-2191 treatment was punctate keratitis, a frequently observed side effect of intravitreal methotrexate, that was most commonly mild in severity.

07:07 EST EyePoint expects cash expects cash to fund operations through H2 of 2024 - The company said, "We expect the cash, cash equivalents and investments on hand on December 31, 2022 and expected net cash inflows from our product sales will enable us to fund our current and planned operations into the second half of 2024."

07:02 EST Big Lots sees Q1 SSS down the low to mid-teens range - For the first quarter, the company expects comps to be down in the low to mid-teens range. Net new stores will add about 40 basis points of growth versus 2022. The company expects the first quarter gross margin rate to improve sequentially versus Q4 into the high-30s range. Given an atypically wide range of potential outcomes, the company is not providing EPS guidance at this point. The company expects a share count of approximately 29.1M for Q1. With regard to the full year, the company is targeting improvement in financial results versus 2022. Earnings momentum will be weighted towards the back half of the year, as key actions to improve the business gain traction, and as freight cost reductions continue to be realized. Given greater than usual uncertainty in the macroeconomic environment, at this point the company is not providing formal full year guidance.

07:02 EST Bristol-Myers and Johnson & Johnson launch Phase 3 trial of milvexian - Bristol Myers Squibb (BMY), in collaboration with Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson and Johnson (JNJ), announced the launch of the Phase 3 Librexia program studying milvexian, an investigational oral factor XIa - FXIa - inhibitor. The Librexia program is the most comprehensive FXIa development program to date and will provide data from nearly 50,000 patients across three indication-seeking studies. Enrollment has begun for the Librexia STROKE trial, which is evaluating milvexian in addition to standard of care antiplatelet therapy for stroke prevention in patients after an acute ischemic stroke or high-risk transient ischemic attack. The Librexia ACS trial, which will evaluate event reduction in acute coronary syndromes in addition to standard of care antiplatelet therapy, and the Librexia AF trial, which will investigate milvexian compared to apixaban in the prevention of stroke in patients with atrial fibrillation, will also initiate during the first half of 2023. Phase 2 proof-of-concept data for milvexian demonstrated a differentiated antithrombotic profile as both a monotherapy and in combination with antiplatelet therapy. Librexia ACS and Librexia AF trials are expected to begin enrolling within the first half of 2023.

06:52 EST The Buckle reports February comparable store net sales down 6.9% vs. last year - Net sales for February decreased 6.1% to $82.5M from net sales of $87.9M for the prior month ended February 26, 2022.

06:50 EST Macy's reports Q4 gross margin 34.1%, down from 36.5% in 4Q21 - Merchandise margin declined largely due to planned markdowns and promotions, which were higher relative to last year, when inventory constraints in the industry led to low promotional levels and robust full-price sell-throughs. The higher level of markdowns and promotions was reflective of both the company's commitment to end 2022 with inventories at the right level and composition, as well as its response to the competitive retail environment. Delivery expense as a percent of net sales was 60 basis points lower than the prior year due to a 200 basis points decline in digital penetration combined with lower peak delivery surcharges.

06:48 EST Macy's to take 'balanced approach' to expense management, capital allocation - Adrian Mitchell, CFO said, "We have built a solid foundation for long-term, profitable growth through enterprise-wide investments in our supply chain, data and analytics, pricing science, digital and technology which have enabled our operations and talented teams to become more efficient and flexible. Looking ahead, we will continue to take a balanced approach to expense management and capital allocation. With an ongoing focus on maintaining our financial health and strong balance sheet, we will make disciplined investments to drive growth while returning capital to shareholders." "We successfully navigated 2022 from a position of financial and operational strength. Despite an increasingly volatile macroeconomic climate, through the ongoing execution of our Polaris strategy, we remained agile, pivoted to meet customer demand and elevated our approach to inventory management," said Jeff Gennette, chairman and CEO of Macy's, Inc. "In the fourth quarter, we benefited from our disciplined inventory approach and compelling gift-giving strategy, which allowed us to provide fresh fashion and style at great values for all our customers. We were competitive but measured in our promotions, took strategic markdowns and intentionally did not chase unprofitable sales. As we look to 2023 and beyond, we believe our five growth vectors which include our private brands reimagination, off-mall expansion, online marketplace, luxury brands acceleration and personalized offers and communication will further solidify our modern department store positioning."

06:46 EST Genenta Science: FDA grants Orphan Drug Designation to Temferon - Genenta Science announced that the U.S. FDA has granted Orphan Drug Designation to Temferon for the treatment of glioblastoma multiforme.

06:43 EST CGI Inc. subsidiary extends 10-year partnership with U.S. State Department - CGI Federal, the wholly-owned U.S. operating subsidiary of CGI Inc, announced that it will continue to support consular services for the U.S. Department of State's Bureau of Consular Affairs in the Republic of India. The services will be delivered under a new, 10-year task order awarded in January 2023 under the Global Support Strategy for Overseas Consular Support Services 2.0 contract. Specifically, CGI Federal will leverage its proven CGI Atlas360 solution to provide critical on-site processing support for consular services.

06:13 EST Ensign Group acquires two skilled nursing facilities in Colorado - Ensign Group acquired the operations of Hampden Hills Post Acute, a 218-bed skilled nursing facility located in Aurora, Colorado, and Mapleton Post Acute, an 84-bed skilled nursing facility located in Lakewood, Colorado. These acquisitions were effective March 1, 2023 and will be subject to long-term, triple net leases. These acquisitions bring Ensign's portfolio to 290 healthcare operations, 26 of which also include senior living operations, across thirteen states.

06:08 EST Six Flags reports Q4 guest spending per capita $65.15 vs. $53.00 last year - Total revenue for fourth quarter 2022 decreased $37M, or 12%, compared to fourth quarter 2021, driven by lower attendance, partially offset by higher guest spending per capita. The decrease in attendance was driven by an increase in ticket prices, the elimination of free tickets and heavily-discounted pass products, and fewer operating days. The company did not open six parks in fourth quarter 2022 that were open for Holiday in the Park in fourth quarter 2021, which accounted for 279 thousand additional guests in fourth quarter 2021. The $12.15 increase in guest spending per capita compared to fourth quarter 2021 consisted of a $6.60 increase in Admissions spending per capita and a $5.55 increase in In-park spending per capita. The increase in Admissions spending per capita was primarily driven by higher realized ticket prices, a higher mix of single day tickets, and revenue from memberships beyond the initial 12-month commitment period, which is recognized evenly each month and was spread over a lower amount of attendance in 2022 versus 2021. The higher In-park spending reflects the company's in-park pricing initiatives, and a strong assortment of retail products, food & beverage offerings, rentals, and new events. The company more than offset the decrease in revenue in the fourth quarter 2022 with lower cash operating costs, driven by full-time headcount reductions, fewer total employee hours worked, and lower advertising costs. These efficiency measures were partially offset by higher wage rates and increases in repair and maintenance, utilities, and other costs due to inflation.

05:45 EST Walgreens with DoorDash, Uber announce free Same Day Rx Delivery for HIV - Walgreens (WBA), in partnership with DoorDash (DASH) and Uber (UBER), announced free, Same Day Rx Delivery of medications for the prevention and treatment of HIV. This service is available to eligible patients within 15 miles of thousands of participating Walgreens retail pharmacies nationwide. This initiative is the latest offering in an ongoing collaboration between Walgreens, DoorDash and Uber. In December 2022, following the companies' response to the White House COVID-19 call to action, the companies launched free Paxlovid delivery services aimed at increasing access to COVID-19 treatment, with a focus on reaching those in socially vulnerable or medically underserved areas.

05:43 EST Amazon announces plans to launch AWS infrastructure region in Malaysia - Amazon Web Services, or AWS, an Amazon company announced plans to launch an AWS infrastructure Region in Malaysia. The new AWS Region will give developers, startups, entrepreneurs, and enterprises, as well as government, education, and nonprofit organizations, greater choice for running their applications and serving end users from data centers located in Malaysia. As part of its commitment to the region, AWS is planning to invest $6B in Malaysia by 2037.

05:39 EST Argenx COO Keith Woods to retire, Karen Massey to succeed - Argenx (ARGX) announced that Karen Massey will join Argenx as COO effective March 13. Massey will succeed Keith Woods, who will remain at Argenx for a transition period to support the launch of subcutaneous efgartigimod, after which he will retire and serve as a strategic advisor on the Commercial Committee of the Argenx board. Massey joins Argenx from Genentech (RHHBY), where she most recently served as senior VP of product development and global clinical operations.

05:13 EST CME Group reports February Aluminum futures ADV of 3,161 contracts - CME Group announced that participation in Aluminum futures is off to a "strong: start in 2023, reporting record average daily volume, or ADV, in February of 3,161 contracts, up 300% year-over-year, as well as record average daily open interest of 2,549 contracts, up 711% year-over-year and extending through December 2024.